Lambert-Eaton Myasthenic Syndrome (LES)

Update on treatment options for Lambert–Eaton myasthenic syndrome: focus on use of amifampridine.   Published online 2011 May 30  Abstract The mainstay of treatment for LEMS is symptomatic but immunotherapy is needed in more severely affected patients. 3, thereby prolonging the action potential and increasing presynaptic calcium concentrations 4-DAP blocks presynaptic potassium channels. 4-DAP for increasing muscle strength and resting compound muscle action potentials has been demonstrated by four placebo-controlled trials the efficacy of 3. More than half of the affected patients have associated small cell lung cancer, and thorough screening for an underlying malignancy is crucial. 4-diaminopyridine (3, amifampridine) has been shown to be more effective 4-DAP, 3, while acetylcholinesterase inhibitors were the first drugs to be used for the amelioration of symptoms. The most common serious adverse events are epileptic seizures. 3, 4-DAP is currently the treatment of choice in p